Antibody Teamwork against Ebola Virus Disease

Matthias Zehner; Florian Klein

doi:10.1016/j.immuni.2020.01.016

Antibody Teamwork against Ebola Virus Disease

Immunity. 2020 Feb 18;52(2):217-219. doi: 10.1016/j.immuni.2020.01.016.

Authors

Matthias Zehner¹, Florian Klein²

Affiliations

¹ Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.
² Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany; Center for Molecular Medicine Cologne, University of Cologne, 50931 Cologne, Germany; Center for Infection Research, Partner site Bonn-Cologne, 50931 Cologne, Germany. Electronic address: florian.klein@uk-koeln.de.

PMID: 32075725
DOI: 10.1016/j.immuni.2020.01.016

Abstract

Antibodies are key components to prevent and treat Ebola virus disease (EVD). In this issue of Immunity, Gilchuk et al. decipher the underlying mechanism of two antibodies that cooperatively target Ebolaviruses. The study provides insight into an antibody combination that potentiates antiviral activity and is able to prevent EVD in nonhuman primates.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Animals
Antibodies, Monoclonal
Antibodies, Neutralizing
Antibodies, Viral
Ebolavirus / immunology*
Hemorrhagic Fever, Ebola*

Substances

Antibodies, Monoclonal
Antibodies, Neutralizing
Antibodies, Viral